Related Experiment Video
Updated: Mar 29, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A
Ali Hindi1, Mohamed Mekkawy2, Hala Shokr1
1Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK.
Pharmaceuticals (Basel, Switzerland)
|March 28, 2026
Summary
Glucagon-like peptide-1 receptor agonists like semaglutide are linked to psychiatric risks, while tirzepatide shows higher injection site reactions and misuse. Liraglutide appears to have a lower risk profile for weight management.
Area of Science:
- Pharmacovigilance
- Clinical Pharmacology
- Public Health
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for weight loss.
- Concerns exist regarding adverse events beyond common gastrointestinal, renal, and pancreatic effects.
- Understanding these risks is crucial for safe clinical practice and policy.
Purpose of the Study:
- To investigate psychiatric risks, administration-related adverse events, and misuse of semaglutide, liraglutide, and tirzepatide for weight management.
- To analyze real-world adverse event data to identify safety signals.
Main Methods:
- Disproportionality analysis using proportional reporting ratios (PRR) and reporting odds ratios (ROR).
- Utilized the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database.
- Excluded gastrointestinal, renal, and pancreatic adverse events to focus on other risks.
Main Results:
- Semaglutide showed significant disproportionality for psychiatric events: anxiety, depression, and suicidal ideation.
- Tirzepatide had higher signals for injection-site reactions and inappropriate use (incorrect dosing, off-label administration).
- Liraglutide exhibited a comparatively lower risk profile.
Conclusions:
- Semaglutide is disproportionately linked to psychiatric adverse events in real-world weight management.
- Tirzepatide is associated with increased injection-site complications and misuse.
- Liraglutide presents a lower risk profile, highlighting the need for monitoring, education, and regulatory oversight for GLP-1 RAs.
Keywords:
GLP-1 receptor agonistsadministration challengesliraglutidepsychiatric adverse eventssemaglutidetirzepatideMore Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
929
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
929
01:06Oral Hypoglycemic Agents: Glinides
936
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
936
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
852
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
852
01:23Dipeptidyl Peptidase 4 Inhibitors
1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K